Alpharma gains exclusive rights for bupivacaine patch
This article was originally published in Scrip
Alpharma is paying up to $263 million for exclusive worldwide rights to develop and commercialise an investigational transdermal bupivacaine patch. The company's Irish affiliate has entered an agreement with Durect Corporation for the latter's Eladur, which is in Phase II trials for the treatment of pain associated with post-herpetic neuralgia. The move will boost Alpharma's strong pipeline of pain management drugs, which includes the Flector Patch (topical diclofenac). Dean Mitchell, Alpharma president and CEO, said that the bupivacaine patch had the potential to "expand the large and rapidly growing market for topical pain products". Under the agreement, Alpharma will pay Durect a $20 million up-front licence fee. In addition, it could pay a further $93 million upon the achievement of predefined development and regulatory milestones spread over multiple clinical indications and geographical regions and up to an additional $150 million in sales-based milestones. Durect will also receive a royalty on product sales if Eladur is commercialised. Alpharma will control and fund the development programme; the transaction is expected to close in the fourth quarter of the year. Eladur delivers bupivacaine for up to three days from a single application;the US FDA has granted it orphan drug designation.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.